Valeant Pharmaceuticals International Inc will focus its acquisition strategy on smaller, private companies in 2015, Chief Executive Michael Pearson said on Thursday. Valeant, whose hostile bid for Allergan Inc failed last year, has no interest in paying for acquisitions with its stock, which the company sees as undervalued, Pearson said on a conference call with analysts to discuss the company's outlook.
Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN traded higher by 0.82% or $1.747/share to $215.86. In the past year, the shares have traded as low as $110.62 and as high as $214.87. On average, 3032380 shares of AGN exchange hands on a given day and today's volume is recorded at 90115.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 3.54% or $5.13/share to $150.25. In the past year, the shares have traded as low as $106.00 and as high as $153.10. On average, 2262340 shares of VRX exchange hands on a given day and today's volume is recorded at 38208.
Source
